Earnings Feed
Start Free
Home/Filings/4/0000935836-26-000031
4//SEC Filing

NODELMAN OLEG 4

Accession 0000935836-26-000031

CIK 0002035832other
View on SEC.govCompany Profile

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 8:28 PM ET

Size

31.3 KB

Accession

0000935836-26-000031

Insider Transaction Report

Form 4
Period: 2026-01-12
Aktis Oncology, Inc.AKTS
EcoR1 Capital, LLC
Director
Transactions
  • Conversion

    Common Stock

    [F1][F2]
    2026-01-12+2,270,879→ 2,270,879 total(indirect: See Note)
  • Conversion

    Common Stock

    [F1][F3]
    2026-01-12+202,862→ 202,862 total(indirect: See Note)
  • Conversion

    Common Stock

    [F1][F4]
    2026-01-12+128,506→ 128,506 total(indirect: See Note)
  • Purchase

    Common Stock

    [F2]
    2026-01-12$18.00/sh+2,077,779$37,400,022→ 4,348,658 total(indirect: See Note)
  • Purchase

    Common Stock

    [F3]
    2026-01-12$18.00/sh+144,443$2,599,974→ 347,305 total(indirect: See Note)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F2]
    2026-01-12−9,913,810→ 0 total(indirect: See note)
    → Common Stock (2,605,878 underlying)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F3]
    2026-01-12−997,299→ 0 total(indirect: See note)
    → Common Stock (262,142 underlying)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F4]
    2026-01-12−488,891→ 0 total(indirect: See note)
    → Common Stock (128,506 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F1][F2]
    2026-01-12−2,397,500→ 0 total(indirect: See note)
    → Common Stock (630,191 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F1][F3]
    2026-01-12−102,500→ 0 total(indirect: See note)
    → Common Stock (26,942 underlying)
  • Conversion

    Class A Common Stock

    [F5][F1][F2]
    2026-01-12+965,190→ 965,190 total(indirect: See note)
    → Common Stock (965,190 underlying)
  • Conversion

    Class A Common Stock

    [F5][F1][F3]
    2026-01-12+86,222→ 86,222 total(indirect: See Note)
    → Common Stock (86,222 underlying)
NODELMAN OLEG
Director
Transactions
  • Conversion

    Common Stock

    [F1][F2]
    2026-01-12+2,270,879→ 2,270,879 total(indirect: See Note)
  • Conversion

    Common Stock

    [F1][F3]
    2026-01-12+202,862→ 202,862 total(indirect: See Note)
  • Conversion

    Common Stock

    [F1][F4]
    2026-01-12+128,506→ 128,506 total(indirect: See Note)
  • Purchase

    Common Stock

    [F2]
    2026-01-12$18.00/sh+2,077,779$37,400,022→ 4,348,658 total(indirect: See Note)
  • Purchase

    Common Stock

    [F3]
    2026-01-12$18.00/sh+144,443$2,599,974→ 347,305 total(indirect: See Note)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F2]
    2026-01-12−9,913,810→ 0 total(indirect: See note)
    → Common Stock (2,605,878 underlying)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F3]
    2026-01-12−997,299→ 0 total(indirect: See note)
    → Common Stock (262,142 underlying)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F1][F4]
    2026-01-12−488,891→ 0 total(indirect: See note)
    → Common Stock (128,506 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F1][F2]
    2026-01-12−2,397,500→ 0 total(indirect: See note)
    → Common Stock (630,191 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F1][F3]
    2026-01-12−102,500→ 0 total(indirect: See note)
    → Common Stock (26,942 underlying)
  • Conversion

    Class A Common Stock

    [F5][F1][F2]
    2026-01-12+965,190→ 965,190 total(indirect: See note)
    → Common Stock (965,190 underlying)
  • Conversion

    Class A Common Stock

    [F5][F1][F3]
    2026-01-12+86,222→ 86,222 total(indirect: See Note)
    → Common Stock (86,222 underlying)
Footnotes (5)
  • [F1]The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.
  • [F2]These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
  • [F3]These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
  • [F4]These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
  • [F5]Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date.
Signature
/s/ Oleg Nodelman, Individually, and as Manager of EcoR1 Capital, LLC|2026-01-12

Documents

1 file

Issuer

Aktis Oncology, Inc.

CIK 0002035832

→
Entity typeother

Related Parties

1
  • filerCIK 0001454385

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 8:28 PM ET
Size
31.3 KB
View on SEC.gov